CD163-targeted crosolic acid-containing liposomes prevent the expression of STAT3 in macrophages, resulting in enhanced anti-tumor immunity by increasing TNF-α, IFN-γ, IL-12 and IL-2 levels, and decreasing the IL-10 level [245]. Here, TNF is linked to neoplasm.